Brokers Issue Forecasts for MLTX Q2 Earnings

MoonLake Immunotherapeutics (NASDAQ:MLTX) – Wedbush issued their Q2 2026 earnings per share (EPS) estimates for MoonLake Immunotherapeutics in a report issued on Monday, September 29th. Wedbush analyst Y. Zhong expects that the company will post earnings per share of ($0.87) for the quarter. Wedbush has a “Outperform” rating and a $18.00 price target on the stock. The consensus estimate for MoonLake Immunotherapeutics’ current full-year earnings is ($1.79) per share. Wedbush also issued estimates for MoonLake Immunotherapeutics’ FY2029 earnings at $3.60 EPS.

MLTX has been the topic of a number of other reports. Guggenheim decreased their price objective on MoonLake Immunotherapeutics from $80.00 to $20.00 and set a “buy” rating on the stock in a report on Tuesday. Rothschild & Co Redburn assumed coverage on MoonLake Immunotherapeutics in a research note on Monday, July 28th. They issued a “neutral” rating and a $65.00 price target on the stock. Redburn Atlantic upgraded MoonLake Immunotherapeutics to a “hold” rating in a report on Monday, July 28th. Stifel Nicolaus lowered shares of MoonLake Immunotherapeutics from a “buy” rating to a “hold” rating and set a $13.00 price objective on the stock. in a report on Monday. Finally, Royal Bank Of Canada reaffirmed a “sector perform” rating and set a $10.00 target price (down previously from $67.00) on shares of MoonLake Immunotherapeutics in a research note on Monday. Three investment analysts have rated the stock with a Buy rating, nine have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $37.00.

MoonLake Immunotherapeutics Stock Performance

MoonLake Immunotherapeutics stock opened at $7.46 on Wednesday. The firm has a 50 day simple moving average of $50.88 and a 200-day simple moving average of $45.26. The stock has a market cap of $479.16 million, a price-to-earnings ratio of -2.68 and a beta of 1.11. The company has a debt-to-equity ratio of 0.21, a current ratio of 16.65 and a quick ratio of 16.65. MoonLake Immunotherapeutics has a 1-year low of $5.95 and a 1-year high of $62.75.

MoonLake Immunotherapeutics (NASDAQ:MLTX) last released its quarterly earnings data on Tuesday, August 5th. The company reported ($0.87) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.73) by ($0.14). During the same period in the previous year, the business posted ($0.39) EPS.

Institutional Trading of MoonLake Immunotherapeutics

Several hedge funds have recently added to or reduced their stakes in the company. Deutsche Bank AG grew its holdings in MoonLake Immunotherapeutics by 59.8% during the 4th quarter. Deutsche Bank AG now owns 903 shares of the company’s stock worth $49,000 after acquiring an additional 338 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its position in shares of MoonLake Immunotherapeutics by 17.9% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 42,236 shares of the company’s stock worth $2,287,000 after purchasing an additional 6,422 shares during the last quarter. Universal Beteiligungs und Servicegesellschaft mbH purchased a new stake in shares of MoonLake Immunotherapeutics during the 4th quarter worth $1,091,000. Harbor Capital Advisors Inc. grew its stake in shares of MoonLake Immunotherapeutics by 28.1% during the first quarter. Harbor Capital Advisors Inc. now owns 102,020 shares of the company’s stock worth $3,986,000 after purchasing an additional 22,372 shares in the last quarter. Finally, Moody Aldrich Partners LLC acquired a new position in shares of MoonLake Immunotherapeutics during the first quarter worth $2,158,000. Institutional investors and hedge funds own 93.85% of the company’s stock.

Insider Buying and Selling at MoonLake Immunotherapeutics

In related news, major shareholder Bihua Chen sold 5,827 shares of the business’s stock in a transaction on Tuesday, September 30th. The stock was sold at an average price of $6.96, for a total transaction of $40,555.92. Following the completion of the transaction, the insider directly owned 1,994,173 shares of the company’s stock, valued at $13,879,444.08. The trade was a 0.29% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Corporate insiders own 12.02% of the company’s stock.

MoonLake Immunotherapeutics Company Profile

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.